

## SUPPORT AGREEMENT

This support agreement (the “**Agreement**”) is made effective as of 20. December 2023 (the “**Effective Date**”) and entered into between Swedish Orphan Biovitrum A/S, Sorgenfrivej 17, 2800 Lyngby (“**Sobi**”) and Denmark's Bleeding Association, Blekinge Boulevard 2, 2630 Taastrup. Att. Head of the Secretariat Karen Binger Holm (the “**Recipient**”).

The above parties may also be referred to jointly as the “**Parties**” and individually as “**Party**”.

WHEREAS, Sobi is an international biopharmaceutical company dedicated to rare diseases;

WHEREAS, Recipient is Head of the Secretariat of Denmark's Bleeding Association;

WHEREAS, Sobi is willing to provide bona fide support to the Recipient for the Purpose (defined below) as set out in the Agreement.

NOW, THEREFORE, the Parties agree as follows:

### 1. TERMS AND CONDITIONS OF SUPPORT

1.1 **Support:** Sobi hereby agrees to assist Recipient for the purpose (the “**Purpose**”) through the provision of support (the “**Support**”) as specified in Schedule 1.

1.2 **Scope:** The Support, including a budget breakdown of how the Support shall be used, is specified in Schedule 1. The Support shall only cover actual, documented, reasonable and direct costs that are necessary in order to meet the Purpose. The Recipient warrants that the Support shall be used solely as set out in Schedule 1 in compliance with this Agreement and all applicable laws, regulations and requirements including any transparency regulations and disclosures.

1.3 **Payment:** The Support will be paid in the following instalment:

16.171 DKK upon signature of this Agreement

1.4 **Payment Terms:** All payments under this Agreement shall be made within thirty (30) days from receipt of an invoice, provided that the invoice specifies the Sobi contact person Julie Trolle.

Sobi's invoice address is:  
Sobi, Sorgenfrivej 17, 2800 Lyngby

1.5 **Follow up and Repayment:** The Recipient shall on a regular basis inform Sobi about the status of the Purpose supported by Sobi, including whether or not the

Purpose has been met. Within sixty (60) days of the earlier of the Purpose End Date (as set out in Schedule 1) or the Purpose having been met, Recipient shall provide Sobi with a signed declaration that the Support has been used in full in accordance with the terms of this Agreement or inform Sobi if any funds provided remain. The Recipient undertakes to repay Sobi any part of the Support if the Purpose is cancelled, this Agreement is terminated pursuant to Section 3.4 or if there are any remaining funds after the earlier of the Purpose End Date or the Purpose having been met. Such payment shall be made within thirty (30) days of the cancellation, termination or meeting of the Purpose.

- 1.6 **No inducement:** The Recipient acknowledges that provision of the Support is in no way an inducement to recommend or purchase a particular medicinal product. If Recipient believes that the Support is in any way intended as, or will serve as, an inducement, Recipient shall immediately notify Sobi.
- 1.7 **Use of Sobi name:** The Recipient may only use the name and logo of Sobi in publications, presentations, programmes, other printed or orally presented materials, after prior review and approval of Sobi.
- 1.8 **Publication of Support:** The Recipient shall be transparent that Support has been provided by Sobi in support of the Purpose. If the Recipient has a website, then this shall include publishing information of the Support on its website. Sobi may use the name or logo of the Recipient to publish the Support on its website, as well as reporting it to all local governing bodies, as appropriate, in accordance with transparency requirements.
- 1.9 **Sobi contact:** Sobi's contact person under this Agreement is Julie Trolle.

## 2. DATA PRIVACY AND TRANSPARENCY

- 2.1 **Data Privacy.** EU privacy law requires that Sobi provide Recipient and/or its representative(s) notice that Sobi and its group companies may use such representatives' personal data (e.g. name and contact details) provided in this Agreement for administration, reimbursement, and internal evaluation purposes. Sobi will process the personal data to the extent necessary to fulfil Sobi's duties under this Agreement and for the purpose of Sobi's legitimate interest as contractor. Sobi may share the representatives' personal data within the Sobi group and with Sobi service providers and agents for the purposes stated in this Section 2.1. Such sharing may include transfer to third countries, i.e. countries outside the EU/EEA area. When transferring the representatives' personal data to third countries, Sobi will ensure that the transfer is subject to appropriate safeguards and that the representatives' rights are protected. Typically, Sobi will enter into standard contractual clauses adopted by the EU Commission with companies in third countries receiving personal data from Sobi. Sobi applies different retention periods

for different categories of personal data. When processing of the representatives' personal data is no longer necessary in relation to the purpose for which it was collected Sobi will erase the personal data. The representatives have the right to access the personal data that Sobi processes concerning the representatives and to request that Sobi rectifies any inaccurate personal data and under certain circumstances request erasure and/or restriction of processing of the personal data. The representatives have the right to object to processing and to receive the processed personal data in a structured, commonly used and machine-readable format and has the right to transmit those data to another controller. The representatives also have the right to lodge a complaint to the local supervisory authority ("Datatilsynet") regarding how Sobi processes such representatives' personal data. Recipient undertakes to share the information provided in this Section 2.1 with all representatives engaged by Recipient or on its behalf in connection with this Agreement and whose personal data will be shared with Sobi.

- 2.2 "Parties"/"Party" further acknowledges and agrees that Sobi has an annual reporting obligation to ENLI (Ethical Committee for the Pharmaceutical Industry) about the HCO/PO they have had a relationship with during the year.
- 2.3 In addition, "Parties"/"Party" acknowledges and agrees that Sobi documents all relationships required to be disclosed with ENLI and maintains the relevant records of the disclosures for a minimum of 5 years after the end of the relevant reporting period (unless a shorter period is required under applicable national data privacy or other laws or regulations). Thereafter the data will be deleted by Sobi.

### 3. MISCELLANEOUS PROVISIONS

- 3.1 **Entire Agreement:** This Agreement, including its Schedules, constitutes the entire understanding between the Parties with respect to the subject matter hereof and supersedes all prior oral or written agreements of the Parties with respect to such subject matter.
- 3.2 **Amendments:** No provision of this Agreement may be amended, modified or otherwise changed, other than by an instrument in writing duly executed on behalf of the Parties to this Agreement.
- 3.3 **Assignments:** This Agreement is personal to the Parties who shall not have any right to assign it without the prior written consent of the other Party, except that Sobi shall have the right to assign the Agreement to its affiliates.
- 3.4 **Termination:** Without limiting any rights or remedies under the governing law pursuant to Section 3.5, Sobi is entitled to terminate this Agreement at any time with immediate effect if in Sobi's reasonable opinion the Recipient commits a material breach of any of its undertakings pursuant to this Agreement, in which case

the Recipient promptly shall see to it that all references to Sobi are removed from its website and any published materials.

- 3.5 **Governing Law and Dispute Resolution:** This Agreement shall be governed and construed by the laws of Denmark. Any dispute, controversy or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity thereof, shall be finally settled by the courts of the above said country.

[Signatures to follow on the next page.]

This Agreement has been signed by each party's duly authorized signatory(ies). This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original and all of which shall constitute together one and the same document. The Parties agree that the execution of this Agreement by electronic means using standard industry signature software and/or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original signatures, and in any proceeding arising under or relating to this Agreement, each Party hereby waives any right to raise any defense or waiver based upon execution of this Agreement by means of such electronic signatures or maintenance of the executed Agreement electronically.

**Swedish Orphan Biovitrum AS**

DocuSigned by:  
*Mia Enochsen*  
E88695B007694FF...

By: Mia Enochsen

Title: Country Manager Denmark & Iceland

Date:

**Denmark's Bleeding Association**

DocuSigned by:  
*Karen Binger Holm*  
DB20472E768C480...

By: Karen Binger Holm

Title: Head of the Secretariat

Date:

## SCHEDULE 1

### THE PURPOSE & THE SUPPORT

The Danish Patient Organization will update the educational material for members / patients with haemophilia.

Sobi wants to support this material in order for the patients and families suffering from haemophilia to get updates material around the disease (disease awareness).

Purpose Start and End Date: 20. December 2023 to end February 2024.

### BUDGET

Opdatering af informationsmateriale om hæmofili

Udgifter	Samlede udgifter i DKK	Egenfinansiering	Søges	Noter
<b>Eksternt layout og print</b> 500 stk., 21x21 cm. i farver Grafisk opsætning og illustrationer Korrekturlæsning 2-3 gange Forsendelse til sekretariat	kr. 23.125		kr. 23.125	A
<b>Lægefaglig kvalitetssikring</b> Kvalificering af pjecens indhold (honorar)	kr. 4.000	kr. 4.000		B
<b>Patientportrætter</b> Bidrag til pjecens indhold (frivillig tid)	kr. 1.800	kr. 1.800		C
<b>Tekstproduktion</b> Tekstredigering Interview med patienter Koordination med læger og patienter, som bidrager Formidling på web	kr. 56.230		kr. 56.230	D
<b>Transport</b> Transport i forbindelse med tre interview af patienter i deres hjem.	kr. 1.500		kr. 1.500	E
<b>Forsendelse</b>	kr. 640	kr. 640		F
<b>Total</b>	DKK 87.295	kr. 6.440	kr. 80.855	

Noter:

A) Baseret på tilbud fra bureauet Synergi, 261023

B) Overlæge fra højt specialiseret hæmofili center kvalificerer pjecens indhold. Der gives et honorar på 4.000 kr. svarende til 8 timer á 500 kr.

C) Tre patienter bidrager med deres egen historie. Estimeret tidsforbrug: 3 timer pr. person, 200 kr./time

D) Kommunikationsmedarbejder, inkl. pension, 8 uger, Magistrenes overenskomst for ansatte i staten.

E) Den estimerede transportudgift pr. patientbesøg er 500 kr.

F) Udsendelse til de to højt specialiserede hæmofili centre og tilhørende børneafdelinger.